Serum S100B represents a new biomarker for mood disorders

Current Drug Targets

Volumn 14, Issue 11, 2013, Pages 1237-1248

  Schroeter, Matthias L ^a,b,c   Sacher, Julia ^a,b   Steiner, Johann ^d   Schoenknecht, Peter ^a   Mueller, Karsten ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b MAX PLANCK INSTITUTE FOR HUMAN COGNITIVE AND BRAIN SCIENCES   (Germany)

^c Leipzig Research Center for Civilization Diseases ^*  (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Astrocytes; Bipolar disorder; DTI; Glia; Imaging; Major depression; Mania; Mood disorder; MRI; Oligodendrocytes; S100B

Indexed keywords

BUSPIRONE; FLUOXETINE; IPSAPIRONE; NEURON SPECIFIC ENOLASE; NEUROTROPHIN RECEPTOR P75; PROTEIN S100B;

AGE; CELL PROLIFERATION; COGNITIVE DEFECT; DEPRESSION; DIFFUSION TENSOR IMAGING; DISEASE ASSOCIATION; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; META ANALYSIS (TOPIC); MOOD DISORDER; MULTIINFARCT DEMENTIA; NERVE CELL PLASTICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; VOXEL BASED MORPHOMETRY; WHITE MATTER;

AGED; AGING; ANIMALS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; HUMANS; MOOD DISORDERS; NEUROGLIA; NEURONAL PLASTICITY; PHOSPHOPYRUVATE HYDRATASE; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT;

EID: 84887968339     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113149990014     Document Type: Review

References (125)

1. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000; 5: 578-93.
2. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: A convergence of mechanisms. Neuropsychopharmacology 2007; 33: 88-109.
3. Rajkowska G. Dysfunction of neural circuits involved in the pathophysiology of mood disorders: Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000; 48: 766-77.
4. Schroeter ML, Abdul-Khaliq H, Sacher J, Steiner J, Blasig IE, Mueller K. Mood disorders are glial disorders: evidence from in vivo studies. Cardiovasc Psychiatry Neurol 2010; 2010: 780645.
5. Cotter D, Pariante CM, Everall IP. Glial cell abnormalities in major psychiatric disorders: The evidence and implications. Brain Res Bull 2001; 55: 585-95.
6. Harrison PJ. The neuropathology of primary mood disorders. Brain 2002; 125: 1428-49.
7. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007; 6: 219-33.
8. Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal volume in major depression in the anterior cingulate cortex. Arch Gen Psychiatry 2001; 58: 545-53.
9. Öngür D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998; 95: 13290-95.
10. Rajkowska G, Miguel-Hidalgo JJ, Wei J. Morphometric evidence for neuronal and glial prefrontal pathology in major depression. Biol Psychiatry 1999; 45: 1085-98.
11. Sacher J, Neumann J, Fünfstück T, Soliman A, Villringer A, Schroeter ML. Mapping the depressed brain: A meta-analysis of structural and functional alterations in major depressive disorder. J Affect Disord 2012; 140: 142-8.
12. Johnston-Wilson N, Sims CD, Hofmann JP, et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder and major depressive disorder. Mol Psychiatry 2000; 5: 142-9.
13. Miguel-Hidalgo JJ, Baucom C, Dilley G, et al. Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry 2000; 48: 861-73.
14. Si X, Miguel-Hidalgo JJ, O'Dwyer G, Stockmeier CA, Rajkowska G. Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacology 2004; 29: 2088-96.
15. Torres-Platas SG, Hercher C, Davoli MA, et al. Astrocytic hypertrophy in anterior cingulate white matter of depressed suicides. Neuropsychopharmacology 2011; 36: 2650-8.
16. Webster MJ, Johnston-Wislon N, Nagata K, Yolken RH. Alterations in the expression of phosphorylated glial fibrillary acidic proteins in the frontal cortex of individuals with schizophrenia, bipolar disorder, and depression. Schizophr Res 2000; 41: 106.
17. Hamidi M, Drevets WC, Price JL. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry 2004; 55: 563-9.
18. Hayashi Y, Nihonmatsu-Kikuchi N, Yu X, Ishimoto K, Hisanaga SI, Tatebayashi Y. A novel, rapid, quantitative cell-counting method reveals oligodendroglial reduction in the frontopolar cortex in major depressive disorder. Mol Psychiatry 2011; 16: 1155-8.
19. Uranova N, Orlovskaya D, Vikhreva O, et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 2001; 55: 597-610.
20. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: A study from the Stanley Neuropathology Consortium. Schizophr Res 2004; 67: 269-75.
21. Vostrikov VM, Uranova NA, Orlovskaya DD. Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res 2007; 94: 273-80.
22. Vostrikov V, Uranova N. Age-related increase in the number of oligodendrocytes is dysregulated in schizophrenia and mood disorders. Schizophr Res Treatment 2011; 2011: 174689.
23. Banasr M, Duman RS. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry 2008; 64: 863-70.
24. Czéh B, Simon M, Schmelting B, Hiemke C, Fuchs E. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology 2006; 31: 1616-26.
25. Khundakar AA, Thomas AJ. Morphometric changes in early-and late-life major depressive disorder: Evidence from postmortem studies. Int Psychogeriatrics 2009; 21: 844-54.
26. Schroeter ML. Die Industrialisierung des Gehirns - Eine Fundamentalkritik der Kognitiven Neurowissenschaften (The industrialization of the mind - Limitations of cognitive neuroscience). Würzburg, Germany: Königshausen & Neumann, 2011.
27. Raponi E, Agenes F, Delphin C, et al. S100B expression defines a state in which GFAP-expressing cells lose their neural stem cell potential and acquire a more mature developmental stage. Glia 2007; 55: 165-77.
28. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calciumdependent and -independent interactions of the S100 protein family. Biochem J 2006; 396: 201-14.
29. Schäfer B, Heizmann C. The S100 family of EF-hand calciumbinding proteins: Function and pathology. Trends Biochem Sci 1996; 21: 134-40.
30. Schroeter ML, Abdul-Khaliq H, Diefenbacher A, Blasig IE. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr Res 2003; 62: 231-6.
31. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: History, function, and expression. Brain Res Bull 1995; 37: 417-29.
32. Pinto SS, Gottfried C, Mendez A, et al. Immunocontent and secretion of S100B in astrocyte cultures from different brain regions in relation to morphology. FEBS Letters 2000; 486: 203-7.
33. Steiner J, Bernstein HG, Bielau H, et al. Evidence for a wide extraastrocytic distribution of S100B in human brain. BMC Neurosci 2007; 8: 2.
34. Schmitt KR, Kern C, Lange PE, Berger F, Abdul-Khaliq H, Hendrix S. S100B modulates IL-6 release and cytotoxicity from hypothermic brain cells and inhibits hypothermia-induced axonal outgrowth. Neurosci Res 2007; 59: 68-73.
35. Akhisaroglu M, Manev R, Akhisaroglu E, Uz T, Manev H. Both aging and chronic fluoxetine increase S100B content in the mouse hippocampus. Neuroreport 2003; 14: 1471-3.
36. Azmitia EC, Whitaker-Azmitia PM. In: Psychopharmacology: The Fourth Generation of Progress; Kupfer D, Bloom F, Eds. New York, USA: Raven Press 1995; pp 443-50.
37. Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O. miR-16 targets the serotonin transporter: A new facet for adaptive responses to antidepressants. Science 2010; 329: 1537-41.
38. Luo KR, Hong CJ, Liou YJ, Hou SJ, Huang YH, Tsai SJ. Differential regulation of neurotrophin S100B and BDNF in two rat models of depression. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1433-9.
39. Manev H, Uz T, Manev R. Glia as a putative target for antidepressant treatments. J Affect Disord 2003; 75: 59-64.
40. Manev H, Manev R. Nomen est omen: Do antidepressants increase p11 or S100A10? J Biomed Discov Collab 2006; 1: 5.
41. Manev H, Manev R. Olanzapine and S100 proteins. Neuropsychopharmacology 2006; 31: 2567.
42. Rong H, Wang G, Liu T, Wang H, Wan Q, Weng S. Chronic mild stress induces fluoxetine-reversible decreases in hippocampal and cerebrospinal fluid levels of the neurotrophic factor S100B and its specific receptor. Int J Mol Sci 2010; 11: 5310-22.
43. Whitaker-Azmitia PM, Murphy R, Azmitia EC. Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology. Brain Res 1990; 528: 155-8.
44. Whitaker-Azmitia PM, Clarke C, Azmitia EC. Localization of 5-HT1A receptors to astroglial cells in adult rats: Implications for neuronalglial interactions and psychoactive drug mechanisms of action. Synapse 1993; 14: 201-5.
45. Alexander B, Warner-Schmidt J, Eriksson T, et al. Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med 2010; 2: 54ra76.
46. Melas PA, Rogdaki M, Lennartsson A, et al. Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. Int J Neuropsychopharmacol 2012; 15: 669-79.
47. Ruf BM, Bhagwagar Z. The 5-HT1B receptor: A novel target for the pathophysiology of depression. Curr Drug Targets 2009; 10: 1118-38.
48. Schmidt EF, Warner-Schmidt JL, Otopalik BG, Pickett SB, Greengard P, Heintz N. Identification of the cortical neurons that mediate antidepressant responses. Cell 2012; 149: 1152-63.
49. Snyder SH. Serotonin, cytokines, p11, and depression. Proc Natl Acad Sci USA 2011; 108: 8923-4.
50. Svenningsson P, Chergui K, Rachleff I, et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 2006; 311: 77-80.
51. Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci USA 2011; 108: 9262-7.
52. Warner-Schmidt JL, Schmidt EF, Marshall JJ, et al. Cholinergic interneurons in the nucleus accumbens regulate depression-like behaviour. Proc Natl Acad Sci USA 2012; 109: 11360-5.
53. Zhang L, Li CT, Su TP, et al. P11 expression and PET in bipolar disorders. J Psychiatr Res 2011; 45: 1426-31.
54. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE. Serum markers support disease-specific glial pathology in major depression. J Affect Disord 2008; 111: 271-80.
55. Schroeter ML, Steiner J, Mueller K. Glial pathology is modified by age in mood disorders - A systematic meta-analysis of serum S100B in vivo studies. J Affect Disord 2011; 134: 32-8.
56. Schroeter ML, Steiner J. Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry 2009; 14: 235-7.
57. Grabe HJ, Ahrens N, Rose HJ, Kessler C, Freyberger HJ. Neurotrophic factor S100beta in major depression. Neuropsychobiology 2001; 44: 88-90.
58. Machado-Vieira R, Schmidt AP, Avila TT, et al. Increased cerebrospinal fluid levels of S100B protein in rat model of mania induced by ouabain. Life Sciences 2004; 76: 805-11.
59. Dean B, Gray L, Scarr E. Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia. Aust N Z J Psychiatry 2006; 40: 217-24.
60. Roche S, Cassidy F, Zhao C, et al. Candidate gene analysis of 21q22: Support for the S100B as a susceptibility gene for bipolar affective disorder with psychosis. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 1094-6.
61. Yang K, Hu YQ, Xie GR, Mao FQ, Su LY. No association of the rs9722 C >T in the S100B gene and susceptibility to major depression in a Chinese population. Genet Test 2008; 12: 487-9.
62. Yang K, Xie GR, Hu YQ, Mao FQ, Su LY. Association study of astrocyte-derived protein S100B gene polymorphisms with major depressive disorder in Chinese people. Can J Psychiatry 2009; 54: 312-9.
63. Dagdan E, Morris DW, Campbell M, et al. Functional assessment of a promoter polymorphism in S100B, a putative risk variant for bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2011; 156B: 691-9.
64. Hohoff C, Ponath G, Freitag CM, et al. Risk variants in the S100B gene predict elevated S100B serum concentrations in healthy individuals. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 291-7.
65. World Health Organization. The ICD-10 classification of mental and behavioural disorders: Diagnostic criteria for research (DCR). Geneva, Switzerland: WHO 1993.
66. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC, USA: American Psychiatric Press 1994.
67. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ, USA: Lawrence Earlbaum Associates 1988.
68. Cooper H, Hedges LV. The Handbook of Research Synthesis. New York, USA: Russell Sage Foundation Publications 1994.
69. Diehl LA, Silveira PP, Leite MC, et al. Long lasting sex-specific effects upon behavior and S100b levels after maternal separation and exposure to a model of post-traumatic stress disorder in rats. Brain Res 2007; 1144: 107-16.
70. Yang K, Xie GR, Hu YQ, Mao FQ, Su LY. The effects of gender and numbers of depressive episodes on serum S100B levels in patients with major depression. J Neural Transm 2008; 115: 1687-94.
71. Streitbürger DP, Arelin K, Kratzsch J, et al. Validating serum S100B and neuron-specific enolase as biomarkers for the human brain - a combined serum, gene expression and MRI study. PLoS One 2012; 7: e43284.
72. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE. Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia - Original research and meta-analysis. Psych Res 2009; 167: 66-72.
73. Potapov EV, Loebe M, Abdul-Khaliq H, et al. Postoperative course of S-100B protein and neuron-specific enolase in patients after implantation of continuous and pulsatile flow LVADs. J Heart Lung Transplant 2001; 20: 1310-6.
74. Steiner J, Bielau H, Bernstein HG, Bogerts B, Wunderlich MT. Increased cerebrospinal fluid and serum levels of S100B in firstonset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry 2006; 77: 1284-7.
75. Mueller K, Sacher J, Arelin K, et al. Overweight and obesity are associated with neuronal injury in the human cerebellum and hippocampus in young adults: a combined MRI, serum marker and gene expression study. Transl Psychiatry 2012; 2: e200.
76. Agelink MW, Andrich J, Postert T, et al. Relation between electroconvulsive therapy, cognitive side effects, neuron specific enolase, and protein S-100. J Neurol Neurosurg Psychiatry 2001; 71: 394-6.
77. Berrouschot J, Rolle K, Kühn HJ, Schneider D. Serum neuronspecific enolase levels do not increase after electroconvulsive therapy. J Neurol Sciences 1997; 150: 173-6.
78. Greffe J, Lemoine P, Lacroix C, et al. Increased serum levels of neuron-specific enolase in epileptic patients and after electroconvulsive therapy - A preliminary report. Clin Chim Acta 1996; 244: 199-208.
79. Machado-Vieira R, Andreazza AC, Viale CI, et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: A possible role for lithium antioxidant effects. Neurosci Lett 2007; 421: 33-6.
80. Abdul-Khaliq H, Schubert S, Stoltenburg-Didinger G, et al. Protein S-100 beta in brain and serum after deep hypothermic circulatory arrest in rabbits: Relationship to perivascular astrocytic swelling. Clin Chem Lab Med 2000; 38: 1169-72.
81. Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. Peripheral markers of blood-brain barrier damage. Clin Chim Acta 2004; 342: 1-12.
82. Kacem K, Lacombe P, Seylaz J, Bonvento G. Structural organization of the perivascular astrocyte endfeet and their relationship with the endothelial glucose transporter: A confocal microscopy study. Glia 1998; 23: 1-10.
83. Schroeter ML, Mertsch K, Giese H, et al. Astrocytes enhance radical defence in capillary endothelial cells constituting the bloodbrain barrier. FEBS Letters 1999; 449: 241-4.
84. Schroeter ML, Müller S, Lindenau J, et al. Astrocytes induce manganese superoxide dismutase in brain capillary endothelial cells. NeuroReport 2001; 12: 2513-7.
85. Kanner AA, Marchi N, Fazio V, et al. Serum S100 - A noninvasive marker of blood-brain barrier function and brain lesions. Cancer 2003; 97: 2806-13.
86. Kapural M, Krizanac-Bengez L, Barnett G, et al. Serum S-100ß as a possible marker of blood-brain barrier dysfunction. Brain Res 2002; 940: 102-4.
87. Marchi N, Rasmussen P, Kapural M, et al. Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci 2003; 21: 109-21.
88. Regner A, Kaufman M, Friedman G, Chemale I. Increased serum S100 beta protein concentrations following severe head injury in humans: A biochemical marker of brain death? NeuroReport 2001; 12: 691-4.
89. Rothermundt M, Falkai P, Ponath G, et al. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 2004; 9: 897-9.
90. Rothermundt M, Ponath G, Arolt V. S100B in schizophrenic psychosis. Int Rev Neurobiol 2004; 59: 445-70.
91. Kögel D, Peters M, König HG, et al. S100B potently activates p65/c-Rel transcriptional complexes in hippocampal neurons: Clinical implications for the role of S100B in excitotoxic brain injury. Neuroscience 2004; 127: 913-20.
92. Ponath G, Schettler C, Kaestner F, et al. Autocrine S100B effects on astrocytes are mediated via RAGE. J Neuroimmunology 2007; 184: 214-22.
93. Wilder PT, Lin J, Bair CL, et al. Recognition of the tumor suppressor protein p53 and other protein targets by the calcium-binding protein S100B. Biochim Biophys Acta 2006; 1763: 1284-97.
94. Carson MJ, Thomas EA, Danielson PE, Sutcliffe JG. The 5-HT5A serotonin receptor is expressed predominantly by astrocytes in which it inhibits cAMP accumulation: A mechanism for neuronal suppression of reactive astrocytes. Glia 1996; 17: 317-26.
95. Porter JT, McCarthy KD. Astrocytic neurotransmitter receptors in situ and in vivo. Progress Neurobiol 1997; 51: 439-55.
96. Eriksen JL, Gillespie R, Druse MJ. Effects of ethanol and 5-HT1A agonists on astroglial S100B. Develop. Brain Res 2002; 139: 97-105.
97. Tramontina AC, Tramontina F, Bobermin LD, et al. Secretion of S100B, an astrocyte-derived neurotrophic protein, is stimulated by fluoxetine via a mechanism independent of serotonin. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1580-3.
98. Kleindienst A, McGinn MJ, Harvey HB, Colello RJ, Hamm RJ, Bullock MR. Enhanced hippocampal neurogenesis by intraventricular S100B infusion is associated with improved cognitive recovery after traumatic brain injury. J Neurotrauma 2005; 22: 645-55.
99. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-9.
100. Arolt V, Peters M, Erfurth A, et al. S100B and response to treatment in major depression: A pilot study. Eur Neuropsychopharmacol 2003; 13: 235-9.
101. Jang BS, Kim H, Lim SW, Jang KW, Kim DK. Serum S100B levels and major depressive disorder: Its characteristics and role in antidepressant response. Psychiatry Investig 2008; 5: 193-8.
102. Hetzel G, Moeller O, Evers S, et al. The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment. Psychopharmacology (Berl) 2005; 178: 161-6.
103. Schroeter ML, Abdul-Khaliq H, Diefenbacher A, Blasig IE. S100B is increased in mood disorders and may be reduced by antidepressive treatment. NeuroReport 2002; 13: 1675-8.
104. Song SK, Sun SW, Ju WK, Lin SJ, Cross AH, Neufeld AH. Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. NeuroImage 2003; 20: 1714-22.
105. Mueller K, Anwander A, Moller HE, et al. Sex-dependent influences of obesity on cerebral white matter investigated by diffusiontensor imaging. PLoS One 2011; 6: e18544.
106. Jones AR, Overly CC, Sunkin SM. The Allen Brain Atlas: 5 years and beyond. Nat Rev Neurosci 2009; 10: 821-8.
107. Tham MW, Woon PS, Sum MY, et al. White matter abnormalities in major depression: evidence from post-mortem, neuroimaging and genetic studies. J Affect Disord 2011; 132: 26-36.
108. Göthe F, Enache D, Wahlund LO, et al. Cerebrovascular diseases and depression: Epidemiology, mechanisms and treatment. Panminerva Med 2012; 54: 161-70.
109. Kales HC, Maixner DF, Mellow AM. Cerebrovascular disease and late-life depression. Am J Geriatr Psychiatry 2005; 13: 88-98.
110. Quinque EM, Arélin K, Dukart J, et al. Identifying the neural correlates of executive functions in early cerebral microangiopathy: A combined VBM and DTI study. J Cereb Blood Flow Metab 2012; 32: 1869-78.
111. Schroeter ML, Buecheler MM, Preul C, et al. Spontaneous slow hemodynamic oscillations are impaired in cerebral microangiopathy. J Cereb Blood Flow Metab 2005; 25: 1675-84.
112. Schroeter ML, Cutini S, Wahl MW, Scheid R, von Cramon DY. Neurovascular coupling is impaired in cerebral microangiopathy - An event-related Stroop study. NeuroImage 2007; 34: 26-34.
113. Xekardaki A, Santos M, Hof P, Kövari E, Bouras C, Giannakopoulos P. Neuropathological substrates and structural changes in latelife depression: the impact of vascular burden. Acta Neuropathol 2012; 124: 453-64.
114. González-Quevedo A, García SG, Concepción OF, et al. Increased serum S-100B and neuron specific enolase - Potential markers of early nervous system involvement in essential hypertension. Clin Biochem 2011; 44: 154-9.
115. Levada OA, Traïlin AV. Serum level of S100B as a marker of progression of vascular mild cognitive impairment into subcortical vascular dementia and therapy effectiveness. Lik Sprava 2012; 3-4: 53-9.
116. Edgar N, Sibille E. A putative functional role for oligodendrocytes in mood regulation. Transl Psychiatry 2012; 2: e109.
117. Donato R. S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001; 33: 637-68.
118. Jow GM, Yang TT, Chen CL. Leptin and cholesterol levels are low in major depressive disorder, bit high in schizophrenia. J Affect Disord 2006; 90: 21-7.
119. Steiner J, Schiltz K, Walter M, et al. S100B serum levels are closely correlated with body mass index: An important caveat in neuropsychiatric research. Psychoneuroendocrinology 2010; 35: 321-4.
120. Steiner J, Schroeter ML, Schiltz K, et al. Haloperidol and clozapine decrease S100B release from glial cells. Neuroscience 2010; 167: 1025-31.
121. Zhang XY, Xiu MH, Song C, et al. Increased serum S100B in never-medicated and medicated schizophrenic patients. J Psychiatr Res 2010; 44: 1236-40.
122. Ahlemeyer B, Beier H, Semkova I, Schaper C, Krieglstein J. S-100beta protects cultured neurons against glutamate-and staurosporine-induced damage and is involved in the antiapoptotic action of the 5 HT(1A)-receptor agonist, Bay x 3702. Brain Res 2000; 858: 121-8.
123. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001; 310: 173-86.
124. Reiber H. Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci 2003; 21: 79-96.
125. Zachrisson OCG, Balldin J, Ekman R, et al. No evident neuronal damage after electroconvulsive therapy. Psychiatry Res 2000; 96: 157-65.